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In spite of tremendous progress in the understanding
of human disease, the search for new mediators con-
tinues as numerous conditions remain poorly under-
stood. In particular in many forms of renal disease,
effective and cause-orientated forms of therapy are still
lacking. The discovery of new pathogenetic mechan-
isms often leads to the development of new drugs with
previously unknown properties which may offer new
treatment modalities. Endothelin is a recently disco-
vered potent biological mediator which exists in three
closely related isoforms (i.e. endothelin-1, -2 and -3
[1-3]. Endothelins belong to a family of 21 amino acid
peptides with two disulphide bridges [1,3]. The main
vascular effects of endothelin are transient vasodilat-
ation and profound and sustained vasoconstriction [4].
Endothelin also exerts marked renal effects, acts as
a mitogen and stimulates proliferation of vascular
smooth muscle and glomerular mesangial cells [5-7].
Important sources of the peptides are endothelial
cells, neurons, renal cells and at least under certain
conditions also vascular smooth muscle cells. Stimuli
for the release of endothelins include hypoxia and/or
ischaemia [8], but also humoral factors (angiotensin
II, vasopressin, transforming growth factor-beta, insu-
lin, thrombin and several cytokines) and potentially
nephrotoxic drugs such as radiocontrast agents, cyclo-
sporin, amphotericin B and OKT-3 [1,3,9,10-22]. On
the other hand, nitric oxide and atrial natriuretic
peptide inhibit endothelin production via a cyclic
GMP-dependent mechanism [1,3,11,20]. In addition,
smooth muscle cells appear to release an inhibitory
factor which limits the production of the peptide. This
may explain why intact tissues such as the blood vessel
wall produce markedly less endothelin than isolated
cells in culture. In vivo in humans, endothelin plasma
levels are very low [21]. However, in different disease
states, elevated endothelin plasma levels have been
described (see below, Table 1).
In the kidney, endothelin reduces renal blood flow
and glomerular filtration rate [10,22-25]; this is mainly
due to vasoconstriction of both afferent and efferent
arterioles. Systemic infusion of endothehn-1 in humans
in vivo leads to blood pressure increase, sodium reten-
tion and reduction in urine flow [24,25]. Although in
vitro endothelin inhibits renin release [23,26], in the
intact organism renin plasma levels do not change or
increase (due to renal vasoconstriction) after infusion
of endothelin-1 [25]. Endothelin stimulates release of
aldosteron, vasopressin and atrial natriuretic peptide
under experimental conditions [9,10]. However, in vivo
in humans, it does not influence the plasma levels of
these hormones [24]. The role of the mitogenic proper-
ties of endothelin [5-7] in the kidney is still unclear,
but it could be involved in proliferative glomerular
diseases.
Endothelins exert their biological effects via activa-
tion of specific receptors. These membrane-bound
receptors have seven transmembrane domains and are
coupled to G-proteins; three types of endothelin recep-
tors have been cloned, i.e. ETA, ETB and ETC receptors
[27]. Endothelin-1, the primary product of endothelial
cells, preferentially activates ETA receptors. ETB recep-
tors exert no isoform specificity and are equally activ-
ated by all endothelin isoforms, while the ETC receptor
preferentially binds endothelin-3 [28]. ETA receptors
on vascular smooth muscle cause vasoconstriction and
mediate proliferation, although ETB receptors contrib-
ute to these effects. Endothelial cells express only ETB
receptors linked to nitric oxide and prostacyclin forma-
tion. The endothelin receptors on renal cells have only
partially been characterized. However, the ETA recep-
tors seem to be expressed mainly in the glomerulus,
the vasa recta bundle and the arcuate artery, while the
ETB receptor predominates in the initial and terminal
Table 1. Possible role of endothelin in disease
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Heart disease
Vascular disease
Hypertension
Other
Myocardial infarction
Coronary spasm
Cardiac shock
Heart failure
Atherosclerosis
Takayashu's disease
Raynaud's disease
Arterial hypertension (?)
High altitude pulmonary hypertension
Migraine
Subarachnoid haemorrhage
Renal failure
Hepatorenal syndrome
Low tension glaucoma
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inner medullary collecting duct and also in the glomer-
ulus [29].
Recently, new molecules have been synthesized,
which in vitro inhibit the effects of endothelin (Table 2)
[30-34]. Certain of these molecules inhibit ETA recep-
tors only, while others interfere with both ETA and
ETB receptors. As both ETA and ETB receptors are
expressed on vascular smooth muscle also in the human
[35-37], combined antagonists more effectively inter-
fere with the vasoconstrictor effects of endothelin. On
the other hand, non-selective endothelin antagonists
also reduce the release of nitric oxide and prostacyclin
from the endothelium and hence the potentially bene-
ficial vasodilator effects of endothelin. In the human
skin microcirculation in vivo, both combined and select-
ive endothelin antagonists potently inhibit the vasocon-
strictor effects of endothelin-1 [38]. In the kidney, it
appears that both receptors contribute to the effects of
endothelin. However, although both ETA and ETB
receptors are present, their distribution in the kidney
is not uniform suggesting different function [29].
Hence, it is likely that combined endothelin antagonists
are required to interfere with the renal effects of
endothelin.
Several experimental studies suggest a pathophysiol-
ogic role of endothelin in renal failure. Indeed, acute
ischaemic renal failure leads to an increase in endo-
thelin release and/or endothelin receptor upregulation
[39-42]; this effect can be reversed by endothelin
receptor antagonists or drugs blocking the endothelin
converting enzyme [43-45]. In uraemic patients, endo-
thelin plasma levels are elevated [46]. In particular,
renal failure induced by nephrotoxic agents seems to
be related to increased endothelin levels; this is true
for radiocontrast agents independent of their type
[47-50], as well as for other potentially nephrotoxic
drugs, like amphotericin B [51] and possibly cisplatin
[52]. Immunosuppressive agents such as cyclosporin
and FK 506 also modulate endothelin release (see
below). Obviously, acute renal failure can be caused
by a variety of stimuli and the importance of a given
mediator may vary depending on the major cause
involved. Ischaemic renal failure is relatively well
defined experimentally and is particularly suitable for
studies with newly developed drugs. Indeed, in a
monkey model, decreases in renal blood flow in acute
ischaemic renal failure could be prevented by an
receptor antagonist [53].
Table 2. Endothelin antagonists
Drug Receptor
BE-18257A/B
BQ-162
BQ-123
BQ-153
PD 147953 (=FR 139317)
RO^62005
PD 142893
PD 145065
ETA
ETA
ETA
ETA
ETA
ETVET,,
ETVET,,
ETVET,
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In chronic renal failure, only very few studies exist;
they all found increases in endothelin plasma levels
and/or gene expression [54,55]. The mechanisms
involved are not entirely clear. Endothelin levels could
be increased because of (1) a reduced renal clearance,
(2) loss of inhibitory mechanisms in renal failure or
(3) due to stimulatory effects, i.e. of uraemic toxins.
In patients with renal failure an endogenous inhibitor
of the 1-arginine/nitric oxide pathway (i.e. dimethylar-
ginine or ADMA [55] accumulates. The inhibition of
nitric oxide production could explain an increased
endothelin production as nitric oxide reduces endo-
thelin production from the blood vessel wall via a
cGMP-dependent mechanism [11]. Patients on haemo-
dialysis also have elevated plasma endothelin levels
[46]. The volume contraction after haemodialysis
seems to increase plasma levels of endothelin further,
possibly through an activation of the sympathetic
nervous system [46,57,58], which is known to increase
plasma endothelin levels [59,60]. This may explain
the differences observed between peritoneal dialysis
(CAPD) and no dialysis on the one hand and haemo-
dialysis on the other, although this is controversial
[46,58]. High-flux membranes (PAN, PMMA, CTA)
seem to clear endothelin better than normal membranes
[61]. Whether these findings reflect a pathogenetic role
for endothelin in chronic renal disease in humans will
be clarified by appropriate clinical studies with endo-
thelin antagonists in the future.
In disease states with secondary involvement of the
kidney—like diabetes [62], hepatorenal syndrome [63],
thrombotic thrombopenic purpura [64], septic shock
[65,66], but also in congestive heart failure [67-70]
and severe atherosclerosis [71]—elevated plasma levels
of endothelin have been described and may contribute
to the deterioration of renal function occurring under
these conditions. Ongoing experimental and clinical
trials with endothelin antagonists will elucidate the
pathogenic role of endothelins in these disease states
and its involvement in renal functional impairment in
particular. Similarly, in autoimmune diseases like
Morbus Wegener and Morbus Raynaud [59], elevated
endothelin plasma levels occur. In a mice lupus neph-
ritis model, endothelin gene expression is increased
and tends to normalize with prednisolone therapy [72].
It is conceivable, therefore, that inflammatory diseases
of the vascular wall or the glomerulus are associated
with an activation of the endothelin axis. Whether or
not such an activation is primary or secondary in
nature in these diseases requires experimental and later
clinical studies with specific endothelin receptor
antagonists.
The role of endothelin in arterial hypertension is
controversial (see [2,73]). Infusion of endothelin does
increase blood pressure in experimental animals and
in humans [10,74]. Moreover, patients with endothelin-
secreting haemangioendotheliomas are hypertensive
[75]. Whether or not endothelin production is altered
in hypertension is uncertain. Although some studies
found increased plasma levels of endothelin, many
other studies found no differences as compared to
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controls. However, circulating endothelin may not
reflect local levels of the peptide, as in the blood vessel
wall endothelin is primarily released abluminally [76].
Indeed, in DOCA-salt hypertension vascular endo-
thelin production is increased in the presence of normal
plasma levels of the peptide [77]. In the SHR, however,
both circulating and vascular endothelin is suppressed.
Similarly, in the renal medulla of the SHR, the endo-
thelin content is reduced [78]. These experimental
findings suggest that endothelin may be differently
involved in different forms of hypertension, possibly
also in the human. To further elucidate the role of
endothelin, transgenic and gene knockout rats have
been produced. Endothelin-2 transgenic rats are norm-
otensive (possibly because of the activation of com-
pensatory vasodilator mechanisms) and endothelin-1
gene knock-out mice are actually hypertensive [79].
For the interpretation of the data derived from the
latter models, one has to be reminded of the fact that
in humans increased endothelin levels, for instance
derived from vascular tumours, do indeed cause hyper-
tension. Moreover, in the human hand vein circulation
of patients with essential hypertension, the vasocon-
strictor response to endothelin is increased. Finally,
endothelin antagonists lower blood pressure in salt-
depleted monkeys in the SHR and DOCA-salt hyper-
tensive rats. The surprising finding that endothelin
knock-out rats have profound malformations of the
throat indicates that the peptide may be importantly
involved in the development of these organs [79].
Cyclosporin therapy is established in the treatment
of host versus graft rejection. However, the drug often
leads to hypertension and impairs renal function. In
cultured endothelial cells cyclosporin stimulates endo-
thelin production [80,81]. Furthermore, in the renal
medulla of rats [82] and rabbits [83], cyclosporin, and
even more so its metabolites [83], but also FK 506
[84], stimulate the production of endothelin, inhibit
prostacyclin release and in turn lead to renal vasocon-
striction, especially in the afferent arteriole [85]. In
addition, both cyclosporin and FK 506 have cytotoxic
effects in renal cells [84]. In transplant recipients,
cyclosporin increases endothelin levels [86]. In the rat
renal circulation, cyclosporin reduces renal blood flow;
this effect can be prevented or reversed by endothelin
antibodies or endothelin antagonists [87]. However,
whether inhibition of endothelin can prevent cyclospo-
rin-induced side effects, especially nephrotoxicity and
hypertension, has still to be established.
Hence, in summary, the endothelins are a new and
potentially very important family of peptides with
potent effects in the cardiovascular system and the
kidney in particular. Their biological effects could
explain a variety of disturbances occurring in renal
disease and in several forms of hypertension. Of great
interest for renal physiologists and nephrologists is the
fact that the endothelin system is activated in several
renal diseases and that endothelin antagonists are
effective in reversing impaired renal function in experi-
mental models. Definitive proof for an involvement of
endothelins in renal function and disease in humans
T. F. Luscher and R. R. Wenzel
awaits the results of ongoing clinical trials with new
and specific endothelin receptor antagonists.
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